Ipratropium Bromide

Hyperkalemia, Acute Bronchitis, Pneumonia + 18 more

Treatment

9 FDA approvals

20 Active Studies for Ipratropium Bromide

What is Ipratropium Bromide

Salbutamol

The Generic name of this drug

Treatment Summary

Ipratropium is an anticholinergic medication that is taken through inhalation. It was developed by Boehringer Ingelheim and was approved by the FDA in 1986 for individual use and 1996 for use in combination with albuterol. It works by producing a local effect but does not cause significant absorption into the body.

Proair HFA

is the brand name

image of different drug pills on a surface

Ipratropium Bromide Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Proair HFA

Salbutamol

1981

314

Approved as Treatment by the FDA

Salbutamol, also known as Proair HFA, is approved by the FDA for 9 uses like Chronic Obstructive Pulmonary Disease and Bronchospasm, Exercise-Induced .

Chronic Obstructive Pulmonary Disease

Used to treat Chronic Obstructive Pulmonary Disease (COPD) in combination with Ipratropium

Bronchospasm, Exercise-Induced

Bronchial Spasm

prophylaxis of Exercise-induced bronchospasm

Bronchospasm

Bronchodilator Agents

Used to treat need of more than one bronchodilator in combination with Ipratropium

Asthma, Exercise-Induced

prophylaxis of Bronchospasm

Exercise-Induced Bronchospasm

Effectiveness

How Ipratropium Bromide Affects Patients

Ipratropium is a medication that helps to relax the muscles in your airways and makes it easier to breathe. It usually takes 1-2 hours for this medication to start working and its effects typically last between 4-6 hours. In clinical trials, ipratropium was found to help improve breathing and lung function in people with asthma. However, it is not known if taking ipratropium regularly or as a preventative measure is beneficial.

How Ipratropium Bromide works in the body

Ipratropium works by blocking the activity of acetylcholine in the airways, which prevents them from constricting. This effect allows the airways to stay relaxed and open, leading to bronchodilation and fewer secretions. At the cellular level, ipratroium stops the acetylcholine from contracting the muscle cells and narrowing the airways.

When to interrupt dosage

The prescribed dosage of Ipratropium Bromide is contingent upon the indicated condition, including Chronic Obstructive Pulmonary Disease (COPD), Asthma and Non-Allergic Rhinitis. The measure of dosage fluctuates, as per the administration approach noted in the table below.

Condition

Dosage

Administration

Pneumonia

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

prophylaxis of Bronchospasm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Emphysema

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Asthma, Exercise-Induced

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Respiratory Tract Infections

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

excess mucus or phlegm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Airway secretion clearance therapy

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Acute Bronchitis

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Bronchitis, Chronic

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Influenza

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Bronchodilation

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Bronchial Spasm

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Bronchitis

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Hyperkalemia

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Asthma

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Respiratory Sounds

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Chronic Obstructive Pulmonary Disease

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Bronchospasm, Exercise-Induced

2.0 mg/mL, , 2.5 mg/mL, 0.09 mg, 3.0 mg/mL, 2.0 mg, 4.0 mg, 8.0 mg, 0.75 mg/mL, 1.5 mg/mL, 25.0 mg/mL, 0.63 mg/mL, 1.25 mg/mL, 0.108 mg, 5.0 mg/mL, 2.4 mg, 0.045 mg, 3.0 mg, 0.4 mg, 0.2 mg, 0.1 mg, 0.05 %, 0.1 %, 0.2 %, 0.83 mg/mL, 0.12 mg, 4.8 mg, 0.00009 mg/mg, 1.0 mg/mL, 0.1 mg/dose, 0.5 mg/mL, 0.2 mg/pump actuation, 0.097 mg/pump actuation, 0.1 mg/pump actuation, 0.4 mg/mL, 0.25 mg/mL, 0.12 mg/pump actuation

, Oral, Syrup, Syrup - Oral, Solution - Respiratory (inhalation), Respiratory (inhalation), Solution, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Intrabronchial, Solution - Intrabronchial, Solution - Oral, Aerosol, metered - Oral, Tablet, Occlusive dressing technique, Syrup - Occlusive dressing technique, Tablet, extended release, Tablet, extended release - Oral, Powder, Powder - Respiratory (inhalation), Liquid, Intramuscular, Liquid - Intramuscular, Capsule - Respiratory (inhalation), Capsule, Liquid - Respiratory (inhalation), Powder, metered, Powder, metered - Respiratory (inhalation), Spray, metered, Spray, metered - Respiratory (inhalation), Aerosol, spray - Oral, Aerosol, spray, Spray, Spray - Oral, Aerosol, metered - Intrabronchial, Inhalant, Nasal, Inhalant - Nasal, Inhalant - Respiratory (inhalation), Solution - Intramuscular, Solution - Intravenous, Liquid - Intravenous, Intravenous, Liquid - Oral, Inhalant - Oral, Solution - Nasal

Warnings

There are 20 known major drug interactions with Ipratropium Bromide.

Common Ipratropium Bromide Drug Interactions

Drug Name

Risk Level

Description

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Hydroxyzine.

Mobocertinib

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Mobocertinib.

Ziprasidone

Major

The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ziprasidone.

1-benzylimidazole

Minor

The risk or severity of hypertension can be increased when Salbutamol is combined with 1-benzylimidazole.

2,5-Dimethoxy-4-ethylamphetamine

Minor

The risk or severity of hypertension can be increased when Salbutamol is combined with 2,5-Dimethoxy-4-ethylamphetamine.

Ipratropium Bromide Toxicity & Overdose Risk

The amount of ipratropium that would be toxic to mice after being taken orally is 1500mg/kg. It is unlikely to overdose on ipratropium due to its poor absorption rate. Ipratropium does not appear to cause cancer, birth defects, or genetic mutation. High doses of ipratropium have been linked to a decrease in fertility rates.

image of a doctor in a lab doing drug, clinical research

Ipratropium Bromide Novel Uses: Which Conditions Have a Clinical Trial Featuring Ipratropium Bromide?

282 active clinical trials are presently investigating the utility of Ipratropium Bromide in alleviating Asthma, Bronchospasm and Perennial Allergic Rhinitis (PAR).

Condition

Clinical Trials

Trial Phases

prophylaxis of Bronchospasm

0 Actively Recruiting

Influenza

28 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 2, Phase 1

Asthma

97 Actively Recruiting

Phase 1, Phase 4, Not Applicable, Early Phase 1, Phase 2, Phase 3

Chronic Obstructive Pulmonary Disease

77 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4

Bronchospasm, Exercise-Induced

0 Actively Recruiting

Hyperkalemia

4 Actively Recruiting

Phase 3, Phase 2, Phase 1, Not Applicable

Bronchitis, Chronic

6 Actively Recruiting

Phase 2, Not Applicable, Phase 4

excess mucus or phlegm

0 Actively Recruiting

Bronchodilator Agents

0 Actively Recruiting

Pneumonia

18 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4

Bronchial Spasm

0 Actively Recruiting

Asthma

10 Actively Recruiting

Phase 2, Not Applicable

Airway secretion clearance therapy

0 Actively Recruiting

Respiratory Sounds

0 Actively Recruiting

Asthma

1 Actively Recruiting

Phase 4

Asthma, Exercise-Induced

0 Actively Recruiting

Emphysema

6 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1

Bronchitis

0 Actively Recruiting

Acute Bronchitis

6 Actively Recruiting

Not Applicable, Phase 3, Early Phase 1, Phase 4

Bronchodilation

0 Actively Recruiting

Ipratropium Bromide Reviews: What are patients saying about Ipratropium Bromide?

5

Patient Review

10/13/2014

Ipratropium Bromide for COPD with Chronic Bronchitis

This medication is a life-saver for those with emphysema and/or bronchitis. It quickly clears the lungs and stops coughing fits, allowing me to live a normal life for over eight years now.

5

Patient Review

6/4/2022

Ipratropium Bromide for Prevention of Bronchospasm with Chronic Bronchitis

Ipratropium has completely changed my quality of life for the better. I had given up hope that anything could help me after 43 years and three surgeries, but this medication was a godsend.

5

Patient Review

10/20/2014

Ipratropium Bromide for Chronic Obstructive Lung Disease

This medication, used in conjunction with Albuterol Sulfate, helped me very quickly. I was pleased with the results.

4.3

Patient Review

9/23/2013

Ipratropium Bromide for Asthma

I get severe muscle cramps as a side effect, but the results for my asthma have been great.

4.3

Patient Review

1/3/2015

Ipratropium Bromide for Chronic Obstructive Lung Disease

I use this in nebulizer form in combination with albuterol. I find that it works for a longer period of time than the rescue inhaler (albuterol only). However, I'm curious if there is a stronger combo available since the percentage of IB contained in one dose is so tiny (0.0173%).

4

Patient Review

10/4/2010

Ipratropium Bromide for Chronic Obstructive Asthma

I used vials of 0.5 mg with 3 mg albuterol in a nebulizer. At first, this was really helpful for my bronchitis and asthma. However, after the third and fourth use I developed severe edema in my legs, ankles, and feet to the point where it hurt to walk. This is apparently a rare reaction, but it's serious enough that I don't want to use the rest of what I have.

4

Patient Review

8/21/2013

Ipratropium Bromide for COPD with Chronic Bronchitis

I have a long-standing history of asthma, COPD and chronic bronchitis. So far, the combination of this treatment and 3.0 albuterol via nebulizer has been successful in keeping me out of urgent care centers.

4

Patient Review

5/4/2012

Ipratropium Bromide for Chronic Obstructive Lung Disease

While this treatment has helped my breathing, it unfortunately also causes my nerves to feel frayed.

4

Patient Review

8/22/2009

Ipratropium Bromide for Asthma

I use this inhaler medication in conjunction with Albuterol and it's been working great!

4

Patient Review

1/12/2009

Ipratropium Bromide for Chronic Obstructive Asthma

I've just started this treatment, and I'm curious about what ingredients are in it (e.g., steroids).

3.7

Patient Review

8/29/2015

Ipratropium Bromide for Asthma

The nebulizer with the Salbutamol Sulphate and ipratropium bromide inhalation solution has been helpful, but I have noticed some concerning side effects. For instance, it makes me dizzy and it's hard to concentrate.

3

Patient Review

3/16/2013

Ipratropium Bromide for Asthma

This medicine caused me to cough when I inhaled it, making it difficult to fully take a breath. My mouth also felt really dry afterwards.

3

Patient Review

1/21/2019

Ipratropium Bromide for Bronchospasm Prevention with COPD

I'm still getting used to this medication, but I am already seeing some improvement in my shortness of breath.

3

Patient Review

7/27/2009

Ipratropium Bromide for Chronic Obstructive Lung Disease

Though this medication did not relieve my shortness of breath, it unfortunately seems to have made it worse. Is there sulfur in this medicine?

2.7

Patient Review

5/9/2010

Ipratropium Bromide for Asthma

This medication does a fair job at relieving my asthma symptoms; however, it comes with the very unpleasant side-effect of causing painful leg cramps that last for days. I've tried drinking tonic water as my doctor recommended, but it doesn't help.

2.7

Patient Review

9/15/2015

Ipratropium Bromide for Emphysema

My first time trying this, my breathing got worse. I tried blowing into ????? but saw only a slight improvement. Will try again later and see what happens.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ipratropium bromide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of ipratropium bromide?

"The following are common symptoms of an ulcer: dizziness, nausea, heartburn, constipation, dry mouth, difficulty urinating, pain when urinating, and frequent need to urinate."

Answered by AI

Is Albuterol the same as ipratropium bromide?

"Both Albuterol and Ipratropium bromide work quickly to provide relief from severe symptoms and breathing difficulties. Ipratropium bromide is an anticholinergic medication, while albuterol is a short-acting beta2- adrenergic agonist."

Answered by AI

Is ipratropium bromide considered a steroid?

"Atrovent (ipratropium) is not a steroid. It is an anticholinergic, which is a type of medication that works differently than steroids to treat runny nose and allergies."

Answered by AI

What is a ipratropium bromide used for?

"Ipratropium is a medication that is used to help manage the symptoms of various lung diseases, such as asthma, bronchitis, and emphysema. It can also be used to help treat blockages in air flow and to prevent the worsening of chronic obstructive pulmonary disease (COPD)."

Answered by AI

Clinical Trials for Ipratropium Bromide

Image of Allergy and Clinical Immunology Associates in Pittsburgh, United States.

Tilrekimig for Asthma

12 - 80
All Sexes
Pittsburgh, PA

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. Tilrekimig or the placebo will be given about every 4 weeks during the study. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

Phase 3
Recruiting

Allergy and Clinical Immunology Associates (+2 Sites)

Pfizer CT.gov Call Center

Pfizer

Image of Seattle Children's Hospital in Seattle, United States.

Follow-Up Strategies for Children With Medical Complexity

1 - 16
All Sexes
Seattle, WA

Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection. Families will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.

Waitlist Available
Has No Placebo

Seattle Children's Hospital

Nassr Nama, MD, MSc

Have you considered Ipratropium Bromide clinical trials?

We made a collection of clinical trials featuring Ipratropium Bromide, we think they might fit your search criteria.
Go to Trials
Image of Rocky Mountain Regional VA Medical Center, Aurora, CO in Aurora, United States.

Low-Dose CT for Lung Cancer Screening

50 - 80
All Sexes
Aurora, CO

Lung cancer screening with low-dose chest computed tomography (CT) is currently recommended for high-risk individuals who are 50 to 80 years old, have smoked cigarettes for at least 20 pack-years, and currently smoke or quit smoking within the past 15 years. In a prospective cohort at Nashville, Denver, Louisville, Chicago, Kansas City, Salisbury and Seattle Veteran Affairs medical centers, the investigators will evaluate the detection of lung cancer using an expanded screening eligibility criteria based on Veterans' personal and service-related exposures compared to standard of care criteria. Screening a larger population will increase the number of lung nodules needing clinical management and these nodules may or may not be cancer. In a population of Veterans with positive screenings at Nashville, the investigators will also validate a combination biomarker-based approach to manage screen-detected lung nodules to reduce time to lung cancer diagnosis and use of invasive procedures. This study will also convene a Veteran Community Advisory Board and interview Veterans to better understand their thoughts about lung cancer screening and preferences for outreach and engagement.

Waitlist Available
Has No Placebo

Rocky Mountain Regional VA Medical Center, Aurora, CO (+6 Sites)

Jennifer A Lewis, MD MS MPH

Bristol-Myers Squibb

Image of Emory University Hospital (EUH) in Atlanta, United States.

Influenza Transmission Study

18 - 49
All Sexes
Atlanta, GA

The purpose of this study is to determine whether influenza A or B can be transmitted from adults with naturally acquired community influenza infection to healthy adult recipients under controlled inpatient exposure conditions, and to identify donor, recipient, viral, immunologic, behavioral, and environmental factors associated with transmission. This study differs from a traditional influenza CHIM because no challenge stock will be administered. Instead, naturally infected community donors will serve as the source of exposure. This approach is intended to better reflect naturally circulating influenza viruses and naturally infected donors while preserving the safety advantages of inpatient monitoring, defined exposure windows, controlled environmental measurements, and standardized sampling.

Waitlist Available
Has No Placebo

Emory University Hospital (EUH) (+1 Sites)

Nadine Rouphael, MD, MSc

Have you considered Ipratropium Bromide clinical trials?

We made a collection of clinical trials featuring Ipratropium Bromide, we think they might fit your search criteria.
Go to Trials
Image of SMS Clinical Research LLC in Garland, United States.

Tilrekimig for Severe Asthma

12 - 80
All Sexes
Garland, TX

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.

Phase 3
Recruiting

SMS Clinical Research LLC (+6 Sites)

Pfizer CT.gov Call Center

Pfizer

Image of St. Michael's Hospital (Unity Health Toronto) in Toronto, Canada.

Treatment for Hyperkalemia

18+
All Sexes
Toronto, Canada

People with end-stage kidney disease who receive hemodialysis are often told to strictly limit foods high in potassium, such as fruits, vegetables, legumes, nuts, and whole grains. This advice is intended to prevent high blood potassium levels (hyperkalemia), which can cause dangerous heart rhythm problems. However, these restrictions can make eating difficult, reduce diet quality, and lower quality of life. New research suggests that not all sources of potassium affect the body in the same way. Potassium added to highly processed foods is more easily absorbed than potassium naturally found in whole foods like fruits and vegetables. Large studies have found little evidence that eating potassium-rich whole foods increases blood potassium levels in people on dialysis. Clinical guidelines are beginning to shift, but no high-quality clinical trial has tested whether a more flexible, food-based approach is safe for people receiving hemodialysis. This study will compare two dietary approaches in 148 adults on hemodialysis: the usual low potassium diet and a "liberalized" potassium diet that encourages minimally processed foods while limiting highly processed foods with potassium additives. Participants will receive dietitian support and grocery assistance for 12 weeks. The investigators will closely monitor blood potassium levels to ensure safety. The investigators will also examine whether the liberalized diet is as safe as standard care, and whether it improves diet quality and quality of life. The investigators will also study factors that influence the participant's ability to follow the diet in real-world settings. If safe, this approach could reduce unnecessary food restrictions, improve diet quality, and enhance quality of life for people receiving hemodialysis, while maintaining patient safety.

Waitlist Available
Has No Placebo

St. Michael's Hospital (Unity Health Toronto)

JoAnne Arcand, PhD, RD

Have you considered Ipratropium Bromide clinical trials?

We made a collection of clinical trials featuring Ipratropium Bromide, we think they might fit your search criteria.
Go to Trials